Applied Therapeutics Logo

Great News From HNF TRIAD Industry Partner — Applied Therapeutics

by | Aug 2, 2023 | 0 comments

Applied Therapeutics, Inc. has announced that their drug candidate, AT-007 (Govorestat), has received orphan medicinal product designation from the European Medicines Agency (EMA) for the treatment of Sorbitol Dehydrogenase (SORD) Deficiency. This designation reflects the high unmet medical need in SORD Deficiency and recognizes the benefit of Govorestat in reducing toxic sorbitol levels. New data published in the Journal of Clinical Investigation has further explained the molecular pathophysiology of SORD neuropathy and the role of sorbitol in neuronal toxicity. This is an important step for advancing regulatory initiatives in Europe and provides certain benefits and incentives for the development and marketing of the medicine.

Learn more on this topic

Related Blog Posts

2024 CMT Roadshow Coming to a City Near You?

2024 CMT Roadshow Coming to a City Near You?

Do you want to make a difference in CMT research? HNF is looking for patients with a confirmed CMT diagnosis to participate in the CMT Biobank

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news